RAPGEF5 and renal cell carcinoma: Likewise, another circRNA, RAPGEF5 (circ-RAPGEF5) was significantly downregulated in RCC tissues, and lower levels of circ-RAPGEF5 demonstrated a positive correlation with aggressive clinical phenotypes (p-value of 0.037), poor survival (p-value of 0.001), and recurrence-free survival.